TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06168084

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vonoprazan
Description: Vonoprazan and amoxicillin dual therapy:given for 14 days at a dose of vonoprazan 20mg 1 tablet BID plus amoxicillin 500 mg 2 capsules TID

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: amoxicillin
Description: Vonoprazan and amoxicillin dual therapy:given for 14 days at a dose of vonoprazan 20mg 1 tablet BID plus amoxicillin 500 mg 2 capsules TID

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bismuth
Description: Bismuth-containing quadruple therapy: given for 14 days at a dose of bismuth 110 mg 2 capsules BID plus esomeprazole 20 mg 2 tablets BID#tetracycline 250mg 2 capsules TID and furazolidone 100mg 1 tablets BID

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Esomeprazole
Description: Bismuth-containing quadruple therapy: given for 14 days at a dose of esomeprazole 20mg 2 tablets BID plus bismuth 110 mg 2 capsules BID#tetracycline 250mg 2 capsules TID and furazolidone 100mg 1 tablets BID

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tetracycline
Description: Bismuth-containing quadruple therapy:given for 14 days at a dose of tetracycline 250mg 2 capsules TID plus furazolidone 100mg 1 tablets BID#esomeprazole 20 mg 2 tablets BID and bismuth 110 mg 2 capsules BID

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Furazolidone
Description: Bismuth-containing quadruple therapy:given for 14 days at a dose of furazolidone 100mg 1 tablets BID plus tetracycline 250mg 2 capsules TID#esomeprazole 20 mg 2 tablets BID and bismuth 110 mg 2 capsules BID
Study: NCT06085508

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Digital patient education to reduce kinesiophobia after MI and/or AF
Description: Group-meetings 7 times via Zoom® video with a tutor (nurse, physiotherapist) and learn about PA, kinesiophobia, AF and/or MI. Scenarios start the problem-based learning process involving recorded lectures, behavioral activation, and exposure to PA. Week1: Programme intro. Formulation of individual goals. Home assignment (HA): Lecture PA after MI/AF. Week 2. Discuss HA. Scenario 1: Why PA after MI/AF? (PBL) Formulate questions\*. HA: Answer the questions. Week 3. Follow-up HA. Scenario 2. What is MI/AF.\* Week 4. Discuss HA. Scenario 3. Living with MI/AF and kinesiophobia - How to make a change?\* HA: Map weekly activities, rate as frightening/non-frightening. List PA and choose one to implement. Use SMART GOALS. Lecture: Kinesiophobia. Week 5. Discuss HA. Scenario 4. How can I reduce my fear for PA.\* SMART, the activity. Week 6. Discuss HA. Week 7. Own individual work. HA: Evaluate, revise, and perform activities. Week 8. Follow-up of the activity plan. Summarize the program.
Study: NCT05759897

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HRS-7535
Description: HRS-7535

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HRS-7535
Description: HRS-7535

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HRS-7535
Description: HRS-7535

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HRS-7535
Description: HRS-7535

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT06527326

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Live Combined Bifidobacterium
Description: the Bifidobacterium genus supplement

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT05834556

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Prehabilitation
Description: Everyone will participate in a home-based prehab program with individual video sessions with a physiotherapist at 4 time points over a period of 3 weeks. The initial session will take an hour and consist of a subjective and physical assessment followed by an individualized exercise program demonstration and education. Patients will be instructed to complete the exercises independently 3x/week. The second and third sessions will be 30 minutes in duration and will check in on activity progress, the presence of abnormal responses to exercise, review exercise technique, address barriers and facilitators to activity completion as well as provide support and encouragement for the current level of activity. The final session will take 30 minutes and will review exercise progress, presence of abnormal responses to exercise followed by a reassessment of physical function.
Study: NCT04675489

Intervention type: OTHER
Group type: OTHER
Intervention: Procedure: Vivity Toric IOL
Description: The U.S. Food and Drug Administration (FDA) has granted approval of Alcon's Vivity Toric Extended Vision intraocular lens (IOL) for cataract patients. This innovative lens is an extended depth of focus IOL that has been reported to result in fewer visual disturbances than diffractive IOLs.
Study: NCT05070507

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Enzyme containing lozenge
Description: Subjects are instructed to take one lozenge three times daily, at least 30 minutes after a meal, for seven days. No oral health care procedures are allowed during the intervention period.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo lozenge
Description: Subjects are instructed to take one lozenge three times daily, at least 30 minutes after a meal, for seven days. No oral health care procedures are allowed during the intervention period.
Study: NCT05346198

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CART-BCMA
Description: The CART-BCMA (study drug) used in this study are chimeric antigen receptor specifically expressing T cells targeting BCMA.
Study: NCT05280392

Intervention type: OTHER
Intervention: Self-administered questionnaires
Description: 4 self-questionnaires given to EHVA T02 participants: at inclusion (Q1, week 0), at the beginning of the ATI period (Q2, week 18), at the end of the ATI period (Q3, date depending on the participant) and at the end of the follow-up period of the clinical trial (Q4, week 54 at the latest)

Intervention type: OTHER
Intervention: Semi-directive individual interviews
Description: With EHVA T02 participants (n=10 to 15): at the end of the follow-up period of the clinical trial.

Intervention type: OTHER
Intervention: Semi-directive individual interviews
Description: With patients who refused to participate to EHVA T02 or patients not included because of negative screening results (n=10 to 15): within 21 days after the refusal or the results of the screening
Study: NCT05308511

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PC-I and COLON2
Description: First swallow the trial device(PC-I) for examination, and then swallow the comparator device(COLON2) for examination at an interval of 2h.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: COLON2 and PC-I
Description: First swallow the comparator device(COLON2) for examination, and then swallow the trial device(PC-I) for examination at an interval of 2h.
Study: NCT06039566

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: IV N-acetylcysteine
Description: N-acetylcysteine (NAC) 150 mg/kg (Max dose 15,000 mg) through an IV that will run for 60 minutes at the start of the procedure

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: IV Placebo
Description: Placebo 0 mg/kg (placebo: 0.45% NaCl or D5W) through an IV that will run for 60 minutes at the start of the procedure.
Study: NCT05983939

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PIPE-791
Description: Single and multiple ascending oral doses of PIPE-791 tablets.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Single and multiple ascending oral doses of matching placebo tablets.
Study: NCT05882656

Intervention type: OTHER
Intervention: Questionnaire administration
Description: All study participants will be surveyed with the EQ-5D-5L questionnaire to measure their quality of life indicators before the primary total hip arthroplasty and after the surgery (on 4 dates over a 1-year period); the WOMAC questionnaire to measure their functional outcomes before the primary total hip arthroplasty and after the surgery (on 4 dates over a 1-year period); the costs questionnaire to measure direct and indirect costs borne by patients because of their condition before the primary total hip arthroplasty and after the surgery (on 4 dates over a 1-year period).
Study: NCT06220916

Intervention type: BEHAVIORAL
Intervention: Dance training in Classical Ballet and Contemporary Dance
Description: Classes, Rehearsals, and Performances of classical ballet and contemporary dance.

Intervention type: BEHAVIORAL
Intervention: Dance training in Classical Ballet and Contemporary Dance
Description: Classes, Rehearsals, and Performances of classical ballet and contemporary dance.

Intervention type: BEHAVIORAL
Intervention: Dance training in Classical Ballet and Contemporary Dance
Description: Classes, Rehearsals, and Performances of classical ballet and contemporary dance.

Intervention type: BEHAVIORAL
Intervention: Dance training in Classical Ballet and Contemporary Dance
Description: Classes, Rehearsals, and Performances of classical ballet and contemporary dance.

Intervention type: BEHAVIORAL
Intervention: Dance training in Classical Ballet and Contemporary Dance
Description: Classes, Rehearsals, and Performances of classical ballet and contemporary dance.

Intervention type: BEHAVIORAL
Intervention: Dance training in Classical Ballet and Contemporary Dance
Description: Classes, Rehearsals, and Performances of classical ballet and contemporary dance.

Intervention type: BEHAVIORAL
Intervention: Dance training in Classical Ballet and Contemporary Dance
Description: Classes, Rehearsals, and Performances of classical ballet and contemporary dance.

Intervention type: BEHAVIORAL
Intervention: Dance training in Classical Ballet and Contemporary Dance
Description: Classes, Rehearsals, and Performances of classical ballet and contemporary dance.
Study: NCT06537505

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Adebrelimab
Description: Q3W,IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Adebrelimab
Description: Q3W,IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apatinib
Description: QoD

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: microwave ablation
Description: microwave ablation

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: microwave ablation
Description: microwave ablation
Study: NCT05251779

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Volatile Oil of Cang-Ai
Description: The test group will be given Volatile oil of Cang-Ai (hereafter referred to as CAVO) for inhalation

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bergamot essential oils
Description: The control group will be given Bergamot essential oils for inhalation.
Study: NCT06540872

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [68Ga]Ga-FAPI-46
Description: Participants receive the weakly radioactive drug \[68Ga\]Ga-FAPI-46 through their vein and lie in an imaging device (PET/MRI) for 30 minutes. After a break of 30 minutes, they will lie in the imaging device for another 15 minutes.
Study: NCT05538039

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Distract with play dough
Description: Distract with play dough

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Distract with play kaleidoscope
Description: Distract with play kaleidoscope

Intervention type: OTHER
Group type: OTHER
Intervention: Control group
Description: Routine nursing care
Study: NCT05497219

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Videofluoroscopic Swallowing Study (VF)
Description: A videofluoroscopy (VF) is a dynamic radiological evaluation of swallowing in which the participant swallows liquid or food boluses of different consistencies prepared with barium contrast. The x-rays are recorded at 30 frames per second.

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Videofluoroscopic Swallowing Study (VF)
Description: A videofluoroscopy (VF) is a dynamic radiological evaluation of swallowing in which the participant swallows liquid or food boluses of different consistencies prepared with barium contrast. The x-rays are recorded at 30 frames per second.

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Videofluoroscopic Swallowing Study (VF)
Description: A videofluoroscopy (VF) is a dynamic radiological evaluation of swallowing in which the participant swallows liquid or food boluses of different consistencies prepared with barium contrast. The x-rays are recorded at 30 frames per second.

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Videofluoroscopic Swallowing Study (VF)
Description: A videofluoroscopy (VF) is a dynamic radiological evaluation of swallowing in which the participant swallows liquid or food boluses of different consistencies prepared with barium contrast. The x-rays are recorded at 30 frames per second.
Study: NCT06425718

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Postoperative Pain Management Technique
Description: Patients who will undergo cesarean section under spinal anesthesia will be included. Comparing postoperative pain and opioid consumption in groups

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Postoperative Pain Management Technique
Description: Patients who will undergo cesarean section under spinal anesthesia will be included. Comparing postoperative pain and opioid consumption in groups
Study: NCT05753592

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Part 1; LOU064 (Remibrutinib)
Description: 25 mg remibrutinib (5.5 days)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Part 2; LOU064 (Remibrutinib)
Description: 25 mg remibrutinib (5.5 days)
Study: NCT05295875

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ALT-801
Description: Injected subcutaneously (SC)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ALT-801
Description: Injected subcutaneously (SC)
Study: NCT06253689

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Defecation Posture Modification Device
Description: Patients assigned to the experimental arm will be asked to use the defecation posture modification device to aid with bowel movements during the postoperative period.
Study: NCT05185674

Intervention type: OTHER
Intervention: Exposure: Coronavirus disease 2019 (COVID-19)
Description: Having presented Coronavirus disease 2019 (COVID-19) and stay in the Intensive Care Unit
Study: NCT05295875

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ALT-801
Description: Injected subcutaneously (SC)

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Injected subcutaneously (SC)
Study: NCT05664711

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bupivacaine Injection
Description: Reciprocal unilateral stellate ganglion blocks, separated by at least 16 hours, will be given once per week for three weeks (for a total of 6 blocks).~This study is not intended to be reported to FDA as a well-controlled study in support of a new indication for bupivacaine or to support any other significant change in the labeling for the drug.
Study: NCT05628142

Intervention type: RADIATION
Group type: OTHER
Intervention: Pelvic CT Scan
Description: Pelvic CT-Scan between 6-12 months post-op
Study: NCT05946629

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PCI with SELUTION SLR DCB
Description: After target lesion pre-dilatation and preparation , a SELUTION SLR 014 PTCA DEB study device should be selected with nominal diameter equal to the RVD of the target lesion (1:1 ratio) and length that allows approximately 2.00 mm longer than the proximal and distal edges of the target lesion (defined as the proximal and distal extent of predilation). If IVUS is performed to assess RVD, and DEB upsizing is deemed clinically necessary for optimal results, a maximum nominal DEB diameter of 3.0 mm is permitted. The SELUTION SLR 014 PTCA DEB should then be delivered, positioned in and deployed per instructions per use. The balloon should be inflated for 60 seconds provided that the patient can tolerate this duration. The minimum inflation time is 30 seconds.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: PCI with FDA approved -limus DES
Description: For subjects randomized to the control group (DES), the treating physician will choose an FDA cleared DES and follow lesion preparation and stent deployment according to the Instructions per use (IFU) and institutional practices.~The DES should be sized per IFU with respect to the vessel RVD. The use of IVUS or OCT is encouraged to guide optimal stent placement and assess final results. After DES deployment, additional balloon inflations should be performed as needed to obtain \< 30% residual diameter stenosis and resolve proximal or distal edge dissections greater than or equal to NHLBI grade B.
Study: NCT06362707

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fasudil
Description: A ROCK inhibitor approved for treating vasospasms following subarachnoidal bleeding in Japan and China. Dosage: Participants will undergo a 2-week titration period at 60 mg daily before escalating to a maintenance dose of 120 mg daily.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo tablets that look identical to the fasudil tablets and will follow the same dosing schedule as participants receiving fasudil.
Study: NCT05910216

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dance & Music (Online)
Description: This is a social telerehabilitation with dance and music. It will include artistic form, imageries using scenic arts, imageries using aspects of theater and storytelling, movement improvisation, choreography and sequence of movements, complex dance movements, fluidity of movement or connection between one movement and another, rhythmicity and/or movement built with music. It will include instructions for motor learning, music, and socialization

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Multimodal Therapeutic Exercise & Music (Online)
Description: This is a social telerehabilitation with multimodal therapeutic Exercise and Music. It is restricted to the execution of movements within series and standardized and fixed repetitions, with a background music. It will not include dance. It will include instructions for motor learning, music, and socialization.
Study: NCT05924347

Intervention type: DIAGNOSTIC_TEST
Intervention: MRI
Description: Longitudinal MRI examination of the thoracic and lumbar spine (T2, T2w, sCT)

Intervention type: DIAGNOSTIC_TEST
Intervention: MRI
Description: Longitudinal MRI examination of the thoracic and lumbar spine (T2, T2w, sCT)

Intervention type: DIAGNOSTIC_TEST
Intervention: Scolioscan
Description: 3D ultrasound of the spine

Intervention type: DIAGNOSTIC_TEST
Intervention: Scolioscan
Description: 3D ultrasound of the spine

Intervention type: DIAGNOSTIC_TEST
Intervention: Skeletal maturity assessment
Description: At one timepoint, a Hand radiograph is taken for digital skeletal maturity assessment

Intervention type: DIAGNOSTIC_TEST
Intervention: Skeletal maturity assessment
Description: At one timepoint, a Hand radiograph is taken for digital skeletal maturity assessment
Study: NCT04639544

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Each participant will consume 1 capsule per day in one of the main meals without any restriction in the diet or in their life habits

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Lactobacillus strain
Description: Each participant will consume 1 capsule per day in one of the main meals without any restriction in the diet or in their life habits
Study: NCT05625659

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Dual-Energy Contrast-Enhanced Spectral Mammography (CESM)
Description: In addition to their standard, digital breast tomosynthesis mammogram (DBT) performed at their regular screening visits, all participants will also receive a contrast-enhanced spectral mammography (CESM). These same diagnostic tests, both the DBT and CESM, with be repeated at 1 year post study entry for all participants. At year 2 post study entry, all participants will return to their usual breast screening exams and no longer received a CESM.
Study: NCT06101940

Intervention type: DIAGNOSTIC_TEST
Intervention: Brain MRI scan
Description: Normal brain MRI scan to evaluate the integrity of the nervous system
Study: NCT05432466

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ACER-002 (celiprolol) 200 mg BID
Description: ACER-002 (celiprolol) 200 mg BID

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo BID
Description: placebo for ACER-002
Study: NCT05459012

Intervention type: OTHER
Intervention: follow-up
Description: Questionnaire of Quality of life
Study: NCT05423639

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: palodent
Description: innovative sectional matrix system with Nickel-Titanium rings, anatomically shaped matrix bands and adaptive self-guiding wedges that provides predictable, tight contacts and restorations that accurately replicate the natural tooth anatomy.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: palodent
Description: innovative sectional matrix system with Nickel-Titanium rings, anatomically shaped matrix bands and adaptive self-guiding wedges that provides predictable, tight contacts and restorations that accurately replicate the natural tooth anatomy.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: optracontact
Description: The instrument is used to achieve large and tight proximal contacts in posterior teeth.
Study: NCT05917080

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Manual Therapy
Description: Manual Therapy: Manual therapy is the use of hands-on techniques to evaluate, treat, and improve the status of Neuro-musculoskeletal conditions.~Augmented Low-Dye Taping: Augmented Low-Dye taping is designed to off-load the plantar fascia \& applied below the ankle and is hypothesised to generate a supinating force that controls the amount of pronation at the subtalar joint.~Neuromuscular Exercises: Neuromuscular training could be defined as training enhancing unconscious motor responses by stimulating both afferent signals and central mechanisms responsible for dynamic joint control.~Strengthening Exercises:The strengthening of the muscles promotes better overall functioning of the foot and thereby can help to take some of the tension out of the fascia.~Stretching exercises:Static stretching is defined as passively stretching a given muscle-tendon unit by slowly placing it maximal position of stretch and sustaining it there for an extended period of time.
Study: NCT05156788

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PD-1+Lenvatinib+GEMOX
Description: Tilelizumab 200mg, add 0.9% NS 100mL, d1 Q3W, Lenvatinib 8mg, po, qd Gemox chemotherapy: Gemcitabine 1000mg/m2 with 0.9% NS 100mL, 30 minutes, d1, 8, Q3W, + oxaliplatin 85mg/m2 with 5%GS 500mL, 2 hours, d1, Q3W